Emerging drugs for Cushing's disease by Guelho, DL & Grossman, AB
1. Background
2. Medical need
3. Existing treatment
4. Current research goals
5. Scientific rationale
6. Competitive environment
7. Potential development issues
8. Conclusion
9. Expert opinion
Review
Emerging drugs for Cushing’s
disease
Daniela Guelho† & Ashley B Grossman
†Department of Endocrinology, Diabetes and Metabolism of Coimbra Hospital and University
Centre, Portugal
Introduction: Considering the effects of uncontrolled hypercortisolism on
morbidity and mortality, there is a clear need for effective medical therapy
for patients with Cushing’s disease (CD). Therefore, the search for new medi-
cal effective tools remains active, and already promising results have been
obtained.
Areas covered: The importance of the design and conduct of trials to validate
old drugs or to test new compounds is discussed. The results of the ongoing
clinical trials, targeting the specific properties of drugs, such as ketoconazole,
LCI699, mifepristone, etomidate and pasireotide, are also reported. The
authors also emphasise the advantages and drawbacks of each particular
drug, and the potential combined use of agents with complementary
mechanisms of action.
Expert opinion: CD is an excellent example of a situation where effective ther-
apy is essential, but where the balance of risk and benefit must be carefully
judged. Metyrapone is the drug of choice when rapid control of the hypercor-
tisolaemia is required, ketoconazole represents a good second-line drug,
although in the future LCI699 may be a better alternative. Mifepristone can
also be used in the rare situation when previous drugs are inappropriate.
Etomidate is useful where immediate parenteral action is required. For drugs
working directly on the pituitary, cabergoline is occasionally effective and
pasireotide can be attempted in patients with mild CD.
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1. Background
1.1 Definition, pathophysiology and clinical presentation
Cushing’s disease (CD), pituitary-dependent Cushing’s syndrome, is a rare disorder
characterised by the overproduction of adrenocorticotrophin (ACTH) [1]. Excess
secretion of ACTH augments cortisol production by the adrenal gland, disturbing
the normal cortisol feedback mechanism of the hypothalamo-pituitary-adrenal
(HPA) axis, with loss of the circadian rhythm and excess cortisol secretion [2]. After
being secreted, glucocorticoids exert their effects through the glucocorticoid recep-
tor (GR), which is expressed in almost every human tissue. Excess glucocorticoids,
such as in CD, result in deleterious effects on cell metabolism, such that patients
develop the clinical features of CD [3]. The clinical presentation of hypercortisolism
varies from patient to patient and includes a wide combination of signs and symp-
toms, such as weight gain, severe fatigue and muscle weakness, depression, cognitive
impairment, purplish skin striae, easy bruising, loss of libido, hirsutism, acne and
menstrual disorders. Hypertension occurs in 80% of patients with Cushing’s syn-
drome and is thought to be mostly caused by the combined effect of cortisol on
both the GR and the mineralocorticoid receptor, although many other factors
may be involved causing enhancement of vasoactive substances and/or a suppression
of the vasodilatory systems, or even by effects on cardiovascular regulation through
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the CNS via both glucocorticoid and mineralocorticoid recep-
tors [4]. In some sites, excess cortisol overwhelms the ability of
type 2 11b-hydroxysteroid dehydrogenase to convert it to cor-
tisone, and thus cortisol has access to and activates the miner-
alocorticoid receptor. Impaired glucose tolerance or
type 2 diabetes also occurs in 80% of patients as a result of
increased insulin resistance and impaired insulin secretion [5].
Glucocorticoids increase liver gluconeogenesis and decrease
glucose uptake in skeletal muscle and adipose tissue [5].
Impaired insulin secretion also occurs as a result of glucocor-
ticoids binding to pancreatic b-cells, resulting in impaired b-
cell function [5].
While in many patients clinical suspicion of Cushing’s syn-
drome is based on a combination of sensitive (central obesity)
and specific (related to protein wasting) signs [6], in other cases
the clinical picture is much less clear and confusing. For this
reason, efficient screening and confirmatory procedures are
essential before considering therapy. Measuring serum cortisol
resistance to dexamethasone, or in blood or saliva at mid-
night, are the most effective ways to detect hypercortisolism.
The final diagnosis, and the search for its cause, requires
sophisticated hormonal testing and imaging procedures best
performed in specialised referral centres [6].
1.2 Approach to the patient with CD
Once the diagnosis of CD is established, treatment should
aim to reverse of clinical features, normalise biochemical
changes with minimal morbidity, and to lead to an improve-
ment in patient well-being, and long-term control of the dis-
ease and the tumour without recurrence [7]. Treatment of all
comorbidities also plays an important role [7].
Transsphenoidal surgery (TSS) is the recommended first-
line treatment of CD [7]. TSS is potentially curative, resulting
in remission of CD in about 65 -- 90% of patients with a pitu-
itary microadenoma, is associated with only a small risk of
complications if performed by an experienced surgeon and
is generally associated with preservation of pituitary func-
tion [7]. However, even among those who achieve remission
post-operatively, a recurrence rate of 10 -- 20% has been
reported in patients followed for more than 5 and 10 years
[8,9]. Repeat TSS may be required in these patients with persis-
tent or recurrent disease to achieve remission in the event of
tumour recurrence, but it is associated with lower remission
rates and higher rates of hypopituitarism [10,11]. Other treat-
ments options include pituitary radiotherapy and bilateral
adrenalectomy, although these are associated with significant
lifelong complications [12].
Radiotherapy (RT) may be recommended for residual or
recurrent disease when further TSS is not appropriate. RT is
also performed to prevent or treat Nelson’s syndrome (NS),
corticotroph tumour progression. The rate of remission of
CD after RT reported in the literature varies considerably [7].
In a recent study, disease remission at 1, 2, 3 and 5 years after
‘gamma knife’ therapy in 96 patients with CD was 34, 54,
72 and 78%, respectively [13]. RT has also been shown to be
effective in controlling tumour growth in more than 90% of
patients [14].
Bilateral adrenalectomy is still used as a definitive treatment
for CD, especially in patients with severe CD, as it will
control hypercortisolaemia immediately. Another important
indication for bilateral adrenalectomy is the treatment of
CD resistant to surgery in women in the reproductive age,
seeking fertility without stimulation of ovulation, as gonado-
trophin deficiency may occur after RT. Bilateral adrenalec-
tomy was traditionally performed through an open
approach, but since the advent of laparoscopic adrenalectomy
the laparoscopic approach has become the surgical method of
choice. Advances in technology and refinement in surgical
skills have greatly reduced morbidity and mortality associated
with adrenalectomy surgery in such a high-risk patient popu-
lation. However, this treatment requires life-long replacement
of glucocorticoids and mineralocorticoids and carries an
increased standardised mortality ratio of about 2.0 [15]. More-
over, adrenalectomy does not treat the pituitary adenoma
itself, and because of the risk of developing NS, MRI scans
and ACTH evaluation have to be performed regularly [16].
Occasionally, adrenal tissue may regrow under the stimulatory
action of chronically elevated ACTH plasma levels [6].
Contrary to other pituitary adenomas such as prolactino-
mas [17] or growth hormone (GH)-secreting adenomas [18] in
which medical treatment has become important, the medical
treatment of CD has traditionally had a marginal role.
Nevertheless, there are numerous circumstances in which the
medical treatment of CD may be indicated.
2. Medical need
There are several indications for medical therapy in CD
(Table 1). The rationale for medical treatment may vary con-
siderably, ranging from a temporary palliative measure to
employing the last available resources and may be an interme-
diary measure in the management of difficult cases.
2.1 Mobility and mortality of CD
The high morbidity and mortality caused by hypercortisolism
justifies the need for effective drugs to control the disease.
Untreated ACTH-dependent Cushing’s syndrome is associ-
ated with a risk of life-threatening cardiovascular, infectious
and metabolic complications [2,19,20] and is associated with
severe morbidity. Chronic hypercortisolism induces major
changes in body composition with abdominal and facial fat
accumulation, muscle and skin atrophy, and osteoporosis [21].
Excess cortisol has also major effects on the brain that can
result in psychopathology and neurocognitive dysfunction [22].
Approximately 55 -- 80% of CD patients have major depres-
sion or an anxiety disorder [23]. Moreover, as mentioned earlier,
CD is accompanied by all components of the metabolic syn-
drome, including overweight/obesity, hypertension, impaired
glucose tolerance/diabetes and dyslipidaemia [21]. CD is associ-
ated with increased mortality, largely due to the high
D. Guelho & A. B. Grossman
2 Expert Opin. Emerging Drugs (2015) 20(3)
Ex
pe
rt 
O
pi
n.
 E
m
er
gi
ng
 D
ru
gs
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
07
/0
3/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
cardiovascular risk. Hypercortisolism induces vascular damage
both directly and indirectly, favouring the occurrence of pre-
mature atherosclerosis [24]. Furthermore, apart from an
increased risk of arterial thrombosis, CD is also associated
with an increased risk of venous thromboembolic disease due
to both activation of the coagulation cascade and impaired
fibrinolysis [25]. Finally, miscellaneous features of CD include
hirsutism, gonadal dysfunction, nephrolithiasis and (most
importantly) increased susceptibility to infection [1].
Depending on their action site, the various medical drugs
available for CD can be classified into three groups: agents
that inhibit adrenal steroidogenesis; drugs that directly target
ACTH secretion and ligands that block the cortisol receptor
(Table 2) [26-28]. Although many drugs have been used ‘off-
label’ to treat CD, currently there are four approved therapeu-
tics for CD. Pasireotide (Signifor, Novartis) is the only
medical therapy approved in the European Union and the
US and is licensed for use in patients for whom surgery is
not an option or has failed [29,30]. Mifepristone (Korlym), a
GR antagonist, is approved in the US for the control of hyper-
glycaemia secondary to hypercortisolism, in patients with
endogenous Cushing’s syndrome who have type 2 diabetes
mellitus or glucose intolerance and have failed or are not
candidates for surgery [31]. Recently, at least in Europe, there
is an on-going expansion of the licences for metyrapone
(Metopirone) and ketoconazole (Ketoconazole HRA). Hope-
fully, this number is likely to rise with the initiation of new
studies and completion of on-going clinical trials.
3. Existing treatment
3.1 Adrenal steroidogenesis inhibitors
Since CD is caused by a pituitary tumour, medical therapy
should ideally target the corticotroph cell adenoma. However,
as glucocorticoids represent the final product of the hypotha-
lamic-pituitary-adrenal axis, steroidogenic inhibition was the
first therapy to be used. Adrenal enzyme inhibitors inhibit
one or more enzymes involved in cortisol synthesis. Combina-
tions of these drugs often have additive or synergistic
therapeutic effects at lower individual doses, thereby minimis-
ing adverse effects. However, the availability of these drugs
varies in different countries. In the US, the most commonly
used drug is ketoconazole; in the UK, metyrapone has been
used more commonly. Both metyrapone and ketoconazole,
marketed by HRA Pharma, have recently been approved for
the treatment of hypercortisolism in the EU. It should also
be noted that many assays for cortisol significantly cross-react
with compound S, 11-deoxycortisol, and this may falsely ele-
vate apparent cortisol levels in patients on metyrapone unless
new mass spectrometric assays are used.
Ketoconazole inhibits the first step in cortisol biosynthesis
(side-chain cleavage) and, to a lesser extent, the conversion of
11-deoxycortisol to cortisol; it is an even more potent inhibi-
tor of C17-20 desmolase, decreasing androstenedione and tes-
tosterone production. Ketoconazole has probably been the
most widely prescribed agent used to inhibit adrenal cortisol
synthesis, but in July 2013 the FDA and European Medicines
Agency issued a safety warning about the use of ketoconazole
for the treatment of fungal infection because of its hepatotox-
icity. Moreover, as it has never been subjected to rigorous
clinical trial, its optimal use has not been fully defined as yet.
Metyrapone is an 11-b-hydroxylase (P450c11) inhibitor
that blocks the final step in cortisol biosynthesis. By decreas-
ing cortisol levels, ACTH increases and stimulates adrenal
androgen production, which can cause an increase in hirsut-
ism in women, thus precluding the use of metyrapone as the
first-line drug for women requiring long-term control of
hypercortisolism. Like ketoconazole, its use for treatment of
CD has been an off-label use, although this is currently chang-
ing. The rate of control of hypercortisolism varies according
to different studies, in part because all such studies were small
and differed in patient characteristics, previous treatment,
medication type and doses, length of follow-up, and criteria
used to define disease control. However, it does seem to
become effective within hours. Valassi et al. demonstrated
urinary-free cortisol (UFC) normalisation in 57% of patients
treated with metyrapone alone, of whom 46% also showed
clinical control of the disease [32].
Etomidate is an intravenous substituted imidazole anaes-
thetic drug that blocks 11-b-hydroxylation of deoxycortisol
to produce cortisol. It may be useful in hospitalised patients,
when infused intravenously at a low dose [33]. It is the only
available agent for patients unable to take medication by
mouth and can be a useful therapy for severe hypercortisolae-
mia in patients intolerant of or unable to take oral
medication.
Mitotane, an adrenocorticolytic drug used primarily for
the treatment of adrenal carcinoma, can also be used to
achieve medical adrenalectomy with or without pituitary irra-
diation in patients with CD [34]. However, its harmful second-
ary effects and the delayed onset of action constitute major
limitations of its use in the treatment of CD [35]. Gastro-
intestinal (47%) and neurological intolerance (30%) are the
most frequent adverse effects reported and, with the exception
Table 1. Indications for medical therapy in Cushing’s
disease.
During preparation for surgery
Patients with contraindication for surgery or a high operation
risk
Patients unwilling to undergo surgery
Patients with low probability of surgical cure (unfavourable
localisation, invisible adenomas…)
Control of metabolic effects of hypercortisolemia in patients
with potential life threatening complications
After unsuccessful surgery or recurrence of the disease
Patients waiting for radiation therapy to take effect
Whenever a definitive treatment is delayed
Metastatic disease
Emerging drugs for Cushing’s disease
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of those with persistent hypercortisolism, almost all patients
required concomitant hydrocortisone replacement [34]. More-
over, it was shown that mitotane can have direct pituitary
effects on corticotroph cells. This drug was demonstrated to
affect cell viability and function of human and mouse
ACTH-secreting pituitary adenoma cells. This inhibitory
effect is caused by mitotane at concentrations corresponding
to the adrenocortical carcinoma therapeutic window [36].
The promising in vitro data showing efficacy of mitotane in
CD at the doses used for adrenocortical carcinoma must be
confirmed in clinical trials, balancing the efficacy of reducing
ACTH secretion with the development of side effects. The
therapeutic window for patients without an adrenocortical
carcinoma is likely to be much less.
3.2 ACTH inhibitors
Contrary to commonly-used medical therapies that do not
target the pituitary tumour, dopamine agonists are potentially
attractive agents for the treatment of CD because they act
directly on the tumour and may have the potential for
decreasing glucose intolerance and diabetes [5]. Indeed, func-
tional dopamine receptor subtype 2 (DR2) is expressed in
approximately 80% of corticotroph pituitary adenomas [37].
However, the results on the efficacy of dopamine agonist ther-
apy in CD have been variable, and few patients experienced
sustained improvement [38]. Bromocritine was shown to cause
an acute decrease in ACTH, but this effect is not sustained
over time with repeated dosing, and only few relatively small
studies have examined the efficacy of cabergoline in patients
with CD. In the study that includes the largest number of
patients with CD treated with cabergoline (n=30), there was
a normalisation of the 24-h UFC in 30% of the patients
who were followed for up to 60 months, at a mean dose of
2.1 mg/week [39]. In patients with CD this drug is used at
higher doses (up to 7 mg/week) than those used in patients
with hyperprolactinaemia. This may raise some concerns
regarding its long-term safety with regard to valvular heart
disease. However, the dose is still significantly lower than
those used for patients with Parkinson’s disease, and the cur-
rent data do not suggest a significant risk in this case [40]. The
relatively low cost of cabergoline and its benign side-effect
profile make it an attractive candidate for drug trials in
patients with CD and a suitable therapeutic alternative during
pregnancy [41].
Somatostatin analogues, and particularly the new multi-
ligand somatostatin analogue, pasireotide, have been demon-
strated to inhibit ACTH release in human corticotroph cells
through interaction with type 5 somatostatin receptors [5,42,43].
As we will see in more detail below, these drugs can represent
an alternative medical approach for CD. Pasireotide injection
has been approved in a number of countries for the treatment
of patients with CD for whom surgery has been unsuccessful
or who are not surgical candidates [29]. It is now available in
Europe and in the US and Canada. The major secondary
effect associated to pasireotide therapy is the development of
hyperglycaemia. Although its efficacy was comprehensively
demonstrated by clinical trials, it presents a significantly
higher cost compared to non-FDA approved drugs.
Retinoic acid (RA), used to treat various types of cancer, is a
natural and synthetic derivative of vitamin A that regulates
diverse cellular growth and differentiation programmes, and
cell survival and death [44]. Its anti-proliferative and ACTH
inhibitory effects have been demonstrated both in vitro and
in experimental animals. In in vitro studies of AtT-20
pituitary ACTH-secreting tumour cells, RA was shown to
causes an inhibition of ACTH secretion [45] seemingly
restricted to ACTH-secreting tumour cells, since in rat normal
pituitary cells neither ACTH, prolactin nor GH are affected by
the treatment. Furthermore, RA inhibits cell proliferation and
induces apoptosis in ACTH-secreting tumour cells [45]. The
in vivo RA effects paralleled the in vitro effects [45].
A randomised study using RA in dogs with CD corroborated
these findings [46]. Dogs were treated with RA (n = 22 dogs)
or ketoconazole (n = 20 dogs) for a period of 180 days. In
the ketoconazole group there were no significant changes in
ACTH or a-MSH at any time studied. In contrast, in the
RA treated dogs, there was a significant reduction in plasma
ACTH and a-MSH over time. The survival time after initia-
tion of treatment was significantly longer in the retinoic acid
group compared with the ketoconazole group. Moreover, in
the ketoconazole group, more than 50% of the animals died
before completing the treatment, usually from complications
of the glucocorticoid excess [46]. No adverse events (AEs)
with RA were recorded, except for one case of footpad hyper-
keratosis. More recently, a prospective multicentre study was
the first to show a marked and prolonged decrease in UFC
in three of seven CD patients, and ameliorated symptoms of
hypercortisolism in five of them [47], supporting the possibility
of RA representing a novel therapeutic approach to CD. In this
series, albeit small, RA showed considerable potential as an
ACTH secretion-restraining agent. Indeed, five of seven
patients exhibited a clear-cut decrease in UFC excretion that
led to normalisation in three cases. Furthermore, clinical fea-
tures of hypercortisolism, in particular glycaemic control and
body weight, were ameliorated. However, there remain doubts
as to whether this will ever be a useful agent in this condition.
3.3 Cortisol receptor blocker
Mifepristone (previously known as RU-486) is an anti-
progestational drug that is best known as an abortifacient.
However, at much higher doses, it also acts as a GR antago-
nist. Apart from treatment of CD patients with hyperglycea-
mia, the role of mifepristone is not clear (as we will in more
detail below) [31], but it may also be a reasonable short-term
intervention for patients with an acute hypercortisolaemic
crisis, such as cortisol-induced psychosis. This is an expensive
drug with some particular pitfalls, such as a risk of
mifepristone-induced hypokalaemia, a lack of available
biological parameters of follow-up, and anti-progestin effects.
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Several other different pharmacological approaches have
been explored. Experimental studies demonstrated that
PPARg agonists blunted ACTH secretion in rodents with
tumoral corticotroph implants [48]. Therefore, PPARg agonists
were hypothesised to reduce ACTH secretion via their anti-
proliferative and pro-apoptotic effect; indeed, tumour growth
was markedly blunted in rodents treated with rosiglitazone.
These promising results, however, did not transfer to humans:
pioglitazone or rosiglitazone administration in patients with
CD failed to reveal consistent reductions in UFC, plasma
ACTH or serum cortisol levels, possibly a consequence of the
low proliferative potential of human ACTH-secreting pitui-
tary tumours [49]. In addition, a potential concern for the
long-term use of rosiglitazone in CD is its pro-osteoporotic
effects, already observed in diabetic patients [50]. Temozolo-
mide, an orally administrated second-generation alkylating
chemotherapeutic agent, could be an efficient drug in cases
of aggressive CD [51]. Temozolomide has shown promise as
monotherapy [52], and in combination with pasireotide [53],
as a treatment for aggressive pituitary adenomas and carcino-
mas, andmay represent another viable treatment option target-
ing aggressive corticotroph adenomas refractory to surgery,
RT, or other medical treatments. In tumours that responded
to temozolomide, a prompt reduction in ACTH, chiasmaticde
compression and reduced mass effects were observed [54].
4. Current research goals
CD is an excellent example of a situation where effective ther-
apy is essential, but where the balance of risk and benefit must
be carefully judged. In the case of CD, the re-evaluation of
available drugs is still a valuable research goal, requiring proof
of the effectiveness and applicability of currently available
therapies. This ‘recycling’ of old drugs can bypass the limita-
tions associated with side effects. Also, clinical trials evaluating
these drugs should be designed with the highest quality stand-
ards, which in general has not always been the case to date.
Additionally, as part of all evolutionary processes, another
important goal is to find new targets and therapeutic agents
to test. The current research goals should identify and evaluate
the efficacy of medical therapy in patients with severe bio-
chemical disturbances (e.g., hypokalaemia), immunosuppres-
sion and/or mental instability, who may need immediate
and life-saving cortisol-lowering therapy. Moreover, patients
with CD are at risk of infection and cardiovascular events
(both ischaemic and thromboembolic), and an evaluation
before surgery is warranted to identify patients at high risk
of perioperative complications and to optimise their overall
health status before the operation. Also, an earlier diagnosis
of patients with a high risk of post-surgical recurrence is
important. Clinico-pathological studies have begun correlat-
ing the behavioural characteristics of pituitary tumours with
histopathological and immunohistochemical features [55].
For CD specifically, the absence of peritumoral Crooke’s
change may be a predictor of recurrence after successful
surgical treatment [56]. The absence of Crooke’s changes indi-
cates a lack of suppression, indicating that corticotroph cells
may have some intrinsic abnormality predisposing to adeno-
matous islands and recurrence [56]. Overall, invasive pituitary
adenomas tend to have a higher proliferative rate and immu-
nopositivity for p53 [55]. Further assessment is required to
characterise the histological features that may help predict
long-term outcome and recurrence.
5. Scientific rationale
5.1 Ketoconazole
Ketoconazole, an imidazole derivative, is an antifungal agent
that, in higher dosages, reduces adrenal steroid production
via inhibition of multiple steroidogenic enzymes. This
drug represents a racemic mixture of the cis enantiomers
(-)-(2S,4R) and (+)-(2R,4S). One enantiomer of ketoconazole
(2S, 4R) has been shown to be responsible for virtually all of
the cortisol synthesis inhibitory activity present in the race-
mate. The industrial preparation of enantiomerically pure
antifungal drugs with a high antifungal activity allows for
the same therapeutic effectiveness using lower dosages than
those required for racemic ketoconazole [57].
Apart from adrenal blocking effects, ketoconazole may also
have direct effects on corticotrophic tumour cells of patients
with CD. Stalla et al. [58] have shown that ketoconazole inhib-
its both basal and stimulated ACTH production by rat ante-
rior pituitary cells. In addition, ketoconazole inhibited cell
growth, in part by the induction of apoptosis. These effects
may explain the absence of a compensatory rise in ACTH
levels in patients with CD during prolonged treatment with
ketoconazole [59], which contrasts with the observed ACTH
increase during chronic treatment with metyrapone [60].
The major side effect of ketoconazole is hepatotoxicity, and
liver function should be monitored carefully during treat-
ment. In addition, ketoconazole can cause hypogonadism in
men and gastrointestinal complaints [61]. It should not be
administered with proton pump inhibitors as it requires
gastric acidity for absorption.
5.2 LCI699
LCI699 is an 18-hydroxylase (aldosterone synthase) inhibitor
and was first characterised as an aldosterone biosynthesis
inhibitor for primary aldosteronism and essential hyperten-
sion. It also inhibits 11b-hydroxylase (CYP11B1) in a similar
manner to the R-enantiomer of fadrozole (FAD286); this
blocks the hydroxylation of deoxycortisol to cortisol as well
as CYP11B2, thus blocking the conversion of deoxycorticos-
terone to corticosterone. As predicted from its mode of action,
LCI699 treatment was associated with falls in circulating cor-
tisol and aldosterone, and a rise in testosterone (in women),
ACTH, 11-DOC and 11-deoxycorticosterone, the latter by
18-fold. The reduction in serum aldosterone was accompa-
nied by a fall in circulating renin, presumably due to a rise
in mineralacorticoids, and hypokalaemia was documented as
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a drug-related adverse reaction. Taken together, these results
suggest that the mineralocorticoid action of 11-deoxycorticos-
terone is sufficient to overcome any benefit from the
inhibition of aldosterone synthase.
The dose of LCI699 required to match the benefit of the
aldosterone antagonist eplerenone has been shown to induce
hypoadrenalism, and this ability to inhibit cortisol secretion
was transformed from a potential adverse reaction to a treat-
ment goal. Currently, LCI699 offers a hope for managing
patients with CD. Having established the ability of LCI699
to safely and effectively reduce cortisol levels in CD, the next
step for researchers is to conduct a follow-up trial that enrols
a greater number of patients, with longer treatment duration.
Despite the similarities in the action mechanisms of
LCI699 and metyrapone [60], LCI699 is a more potent drug
(in vitro IC50 of 7.5 nM vs 2.5 nM for metyrapone) and
appears to be effective at doses around 100 times lower [62].
In addition, LCI699 has a longer half-life [30], allowing a
more convenient dosage schedule. Common AEs are gastroin-
testinal disturbance, including nausea and diarrhoea. And, as
could be anticipated with such a potent drug, some patients
had clinical effects that are consistent with adrenal insufficiency
and/or steroid withdrawal (moderate fatigue, mild nausea, diz-
ziness, mild muscle spasms and moderate hypotension), with
these being effectively managed by a dose reduction.
The initial reports of LCI699 explored its aldosterone syn-
thase (CYP11B2) inhibitory action, at doses of up to 2 mg/d
in patients with primary hyperaldosteronism and essential
hypertension, and demonstrated correction of hypokalaemia
and hypertension [63,64]. The induced hypoadrenalism pre-
cluded the use of this drug, but unleashed the development
of clinical trials evaluating its efficacy and safety in the treat-
ment of CD.
5.3 Mifepristone
Mifepristone, a substituted 19-nor steroid compound, is the
first and currently only available GR antagonist treatment [65].
Other GRs are currently being evaluated, but no clinical trial
has been published to date [66]. Mifepristone blocks the action
of cortisol by binding to the GR (type II) and blocks proges-
terone at the progesterone receptor. Steroid hormone recep-
tors belong to the superfamily of nuclear receptors and
are hormone-dependent transcription factors, positively or
negatively regulating a large set of genes. They consist of a
carboxy-terminal ligand-binding domain, a central DNA-
binding domain that interacts with specific DNA sequences
on target genes, and an N-terminal hypervariable region [67].
The GR is a member of the steroid hormone receptor subfam-
ily of nuclear receptors, ubiquitously expressed in almost all
human tissues and organs. At the cellular level, the GR, an
intracellular receptor protein, mediates the actions of gluco-
corticoids. Many responses have been reported to occur
within seconds or minutes after exposure to glucocorticoids.
Following steroid binding, receptors undergo a conforma-
tional change that is probably crucial for receptor interaction
with cellular targets. Mifepristone, a receptor antagonist,
reversibly maintains the receptor in an inappropriate confor-
mation. Mifepristone binds to the human GR with an affinity
3-4 times higher than that of dexamethasone and about
18 times higher than that of cortisol [68].
Mifepristone also has a strong anti-progestin activity, and a
weak anti-androgen activity. Its affinity for the progesterone
receptor is more than twice that of progesterone, and affinity
for the androgen receptor is less than one third that of testos-
terone. It does not bind to the oestrogen receptor or the
mineralocorticoid receptor. Following oral administration of
a single dose of 400 - 600 mg, mifepristone is rapidly
absorbed, with a peak plasma concentration occurring
approximately 90 min after ingestion. Notably, in the absence
of progesterone or cortisol, mifepristone can also act as a weak
agonist [66]. Mifepristone appears as a rapidly effective drug in
controlling signs of hypercortisolism.
As mentioned, mifepristone has the drawback of important
secondary effects and limitations. About one third of the
patients treated with mifepristone present with hypokalae-
mia [61]: as mifepristone blocks only glucocorticoid action,
the mineralocorticoid activity of cortisol excess is not affected
and can lead to hypokalaemia. The same mechanism can
induce increased blood pressure levels, despite an improve-
ment of the clinical signs of hypercortisolism. Also, during
the treatment with this GR blocker, the levels of ACTH and
cortisol increase, making it difficult to determine the efficacy
of the drug. Management of adrenal deficiency is also
difficult: hydrocortisone is not effective and should be given
in parallel with mifepristone withdrawal. Due to its anti-
progestin effects, this drug can also induce endometrial
hyperplasia, and a pelvic ultrasonography should be
performed yearly in every pre-menopausal woman.
5.4 Pasireotide
Soon after its discovery in 1972, somatostatin was known to
be a major regulator of GH release from the pituitary and
was therefore of interest for the potential treatment of
acromegaly [69]. The production of synthetic somatostatin
analogues with a significantly longer half-life was a major
step forward in the treatment of acromegaly and gastro-
enteropancreatic neuroendocrine tumours. Another impor-
tant step was the discovery of the fivr somatostatin receptor
subtypes. Whereas growth-hormone producing adenomas
generally express high levels of type 2 somatostatin receptor
(sst2), other adenomas, such as corticotroph adenomas, not
only express considerably lower levels of sst2 but also its
expression of sst2 is under negative control by glucocorticoids,
which can be internalised in the hypercortisolaemic state. Pre-
incubation with dexamethasone decreases the expression of
sst2 in corticotrophcells [70]. The type 5 somatostatin receptor
(sst5) seems more resistant to the suppressive effect of gluco-
corticoids, and is expressed at highest level in corticotrophade-
nomas [70]. More recently, sst5 was found to play an especially
crucial role in regulating ACTH release in these cells and that
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sst5-targeting agonists were more effective than sst2-agonists
in inhibiting ACTH release [70].
Pasireotide (SOM230) is a multi-ligand SS-analogue with
high binding affinity for sst2 and sst5, with IC50 values of
1.0 and 0.16 nM, respectively [71]. Its binding profile, which
includes high sst5-affinity, makes it a promising new drug
in the treatment of CD. In preclinical studies, pasireotide
demonstrated inhibition of ACTH secretion in cultured
human corticotroph adenomas [42,72] and in murine AtT20
cells [72,73]. Furthermore, consistently with the model of
glucocorticoid-mediated down-regulation of sstr2, pre-
treatment of AtT20 cells with dexamethasone abolished the
inhibitory effects of octreotide on ACTH secretion, but had
no effect on the inhibitory action of pasireotide or
somatostatin-14 [70]. Somatostatin analogues may also confer
an indirect anti-proliferative effect through inhibition of
angiogenesis (down-regulation of vascular endothelial growth
factor), which limits tumour growth [74], and by reducing
levels of growth factors and trophic hormones [74].
Adenomas from patients with normalised preoperative
UFC excretion had a 10-fold higher sst2 mRNA expression
compared with adenomas from patients with elevated preop-
erative UFC excretion. Moreover, a recently published study
by de Bruin et al. [75] showed that GR-antagonising therapy
with mifepristone was able to induce sst2 expression in vivo
in ACTH secreting neuroendocrine tumours, which was pre-
viously found to be undetectable with somatostatin receptor
scintigraphy. However, whether sustained eucortisolaemia
induced by medical therapy induces re-expression of biologi-
cally active sst2 protein in corticotroph adenomas and, if so,
whether this increases the ACTH-lowering potential of
sst2-preferring somatostatin analogues or pasireotide, remains
to be established. Because somatostatin receptors have also
been found in the normal adrenal cortex and in adrenocortical
tumours, pasireotide could have a potential adrenal-directed
effect in addition to its pituitary-directed effect. However, at
the moment there is no clear evidence of a direct effect of
somatostatin and its analogues at the adrenal level. Further
studies must be carried out on the role of these receptors in
the pathophysiology of the adrenal cortex.
The major drawback associated with treatment with pasir-
eotide is the development of hyperglycaemia, but secondary
effects such as cholelithiasis, diarrhoea, headache and sinus
bradycardia have also been reported. Another potential prob-
lem might be any direct effects of pasireotide therapy on GH
and insulin growth factor 1 (IGF-1evels) in CD patients. It is
well known that pasireotide, via sst5 receptor activation,
directly decreases GH release and hence IGF-1 levels in
patients with acromegaly. In patients with CD, sustained
hypercortisolism by itself causes a state of relative growth-
hormone deficiency and therefore these patients may be at
greater risk of becoming GH-deficient. Current and future
clinical studies with pasireotide in CD patients should there-
fore include careful investigation of the effects on the GH/
IGF-1 axis.
6. Competitive environment
6.1 Ketoconazole
Most of the retrospective studies evaluating the efficacy of
ketoconazole in CD were small, with only two studies enroll-
ing more than 10 patients each, only 100 patients being stud-
ied in total [59,76], and limited patient follow-up. The benefit/
risk balance for using ketoconazole in CD is therefore difficult
to determine (Table 3).
A recent retrospective multi-centre study provided impor-
tant insights on the use of ketoconazole as a sole medical agent
for the treatment of hypercortisolaemia. This study included
200 patients with CD, the largest number ever reported as
being treated with this agent, observed over a 17-year period
in 14 French tertiary centres. When used before TSS in
40 patients for a mean period of 4 months, ketoconazole
resulted in controlled UFC in 49% of patients, partial control
in 36%, and no control in 15%. Clinical improvements in
diabetes, hypertension and hypokalaemia were noted despite
the short duration of therapy with a mean dose of 585 mg/
d. When considering a longer duration of therapy of
160 patients, treated for a mean of 24 months as either pri-
mary or secondary therapy, 50% were controlled, 23% were
partially controlled and 27% were not controlled. These
data suggest that around one-third of the patients on long-
term follow-up were inadequately treated, and that other
medical therapies or other strategies should have been consid-
ered. Approximately 20% of patients had to stop treatment
due to poor tolerability. Mild and major increases in liver
enzymes were observed in 13.5% and 2.5% of patients,
respectively. No fatal hepatitis was observed [77].
Ketoconazole, the (2S,4R) enantiomer contained in the
racemate of ketoconazole, is in Phase III clinical trials at
Cortendo for the treatment of endogenous Cushing’s
syndrome. The company had also been developing the drug
candidate for the treatment of type 2 diabetes; however, no
recent development has been reported for this research.
6.2 LCI699
In a recent proof-of-concept study, adult patients with moder-
ate-to-severe CD ([UFC levels ‡ 1.5 x ULN [upper limit of
normal]) received oral LCI699 for 10 weeks. LCI699 was ini-
tiated at 4 mg/d in two equal doses; the dose was escalated
every 14 days to 10, 20, 40 and 100 mg/d until UFC normal-
ised, whereupon the dose was maintained until treatment
ended (day 70). The primary end point was UFC £ ULN
or a ‡ 50%decrease from baseline at day 70. Twelve patients
were enrolled and completed the study. Baseline UFC ranged
over 1.6 -- 17.0 x ULN. All 12 patients achieved UFC £ ULN
or a ‡ 50% decrease from baseline at day 70; 11 (92%) had
normal UFC levels at that time. After treatment discontinua-
tion (day 84), UFC was £ ULN in 10 patients. Mean
11-deoxycortisol, 11-deoxycorticosterone, and adrenocortico-
tropic hormone levels increased during treatment and
D. Guelho & A. B. Grossman
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declined after discontinuation. Mean systolic and diastolic
blood pressure decreased from baseline by 10.0 and
6.0 mmHg, respectively. LCI699 was generally well tolerated;
most AEs were mild or moderate. The most common AEs
included fatigue (7/12), nausea (5/12) and headache (3/12).
No serious drug-related AEs were reported [62]. Based on these
promising results, the results of larger Phase III trials currently
underway are anticipated.
6.3 Mifepristone
The initial information documenting the efficacy of mifepris-
tone for use in Cushing’s syndrome came from case reports.
In 1985, a patient with Cushing’s syndrome secondary to
ectopic ACTH secretion was treated with mifepristone [78].
Treatment resulted in resolution of clinical effects of
Cushing’s syndrome, redistribution of fat and improvement
in hyperglycaemia and hypertension. However, its approval
by the FDA was only obtained many years later, after an
open-label, 24-week, multi-centre clinical study evaluated
safety and efficacy of mifepristone for the treatment of
Cushing’s syndrome [79]. The SEISMIC study enrolled
50 patients from 17 centres with continued biochemical and
clinical evidence of hypercortisolaemia after failing multimo-
dality therapy, largely surgery and/or RT. Inclusion criteria
were the concomitant presence of type 2 diabetes, impaired
glucose tolerance or hypertension with at least two other signs
or symptoms of Cushing’s syndrome. Forty-three of the
patients had CD, 4 had ectopic ACTH tumours, and 3 had
adrenal carcinomas. In the diabetes cohort, patients were
required to have received stable anti-diabetic regimens before
enrolment and the regimens could not be advanced during the
study. Of the 25 patients in the diabetes cohort who received
mifepristone for at least 30 days, 60% (15 patients) responded
with a 25% or greater reduction in glucose AUC during stan-
dard glucose tolerance testing (p < 0.0001). Eighteen of the
patients (72%) in the diabetes cohort had at least a 25%
reduction in glucose AUC or were able to reduce anti-diabetic
therapy. Mean reduction in A1C was 1.1% from baseline
(p < 0.001), and 6 of 12 patients with an A1C greater than
7% at baseline had an A1C of 6% or less by the end of
the trial. Mean ± s.d. fasting plasma glucose levels were
reduced from 1.49 ± 0.747 mg/mL at baseline to 1.047 ±
0.375 mg/mL at 24 weeks (p < 0.003). The doses of anti-
diabetic drugs were reduced in 7 of 15 patients. Of the
12 patients receiving insulin, 5 were able to reduce their insu-
lin doses by at least 50% [79]. In the hypertension cohort,
8 (38.1%) of 21 patients achieved at least a 5 mmHg reduc-
tion in diastolic blood pressure compared to baseline
(p < 0.05). Two of these responders received spironolactone.
When the change in blood pressure was evaluated in the
hypertensive patients in both cohorts (diabetes plus hyperten-
sion cohort), 42.5% (17 of 40 patients) had a reduction in
diastolic blood pressure of at least 5 mmHg and 27.5%
were able to reduce their antihypertensive drug doses.
However, mean systolic and diastolic blood pressures were
not significantly changed [79].
As patients included in the SEISMIC study represented a
specific subset of individuals, it is unclear how generalisable
these data would be to other patients with CD. Furthermore,
the lack of an appropriate biochemical marker means that, in
clinical practice, dose titrations would need to be based on
clinical signs alone. In SEISMIC, the most common AEs
were nausea, fatigue, headache, decreased blood potassium,
arthralgia, vomiting, endometrial thickening and peripheral
oedema. Adrenal insufficiency was reported in two patients,
and there were five other cases in which symptoms consistent
with adrenal insufficiency led to administration of glucocorti-
coids. Hypokalaemia was common (44%), but was mostly
mild to moderate. Low potassium levels were often associated
with alkalosis and oedema, which were usually reversible with
potassium replacement. An increase in endometrial thickness
was observed in 38% of the females in the study. There
were five cases of vaginal bleeding [80].
The development of a selective GR without anti-progestin
effects could also represent an important step in the long-
term treatment of women with CD. Phase III trials evaluating
the safety, pharmacokinetics and dynamics of mifepristone are
ongoing.
6.4 Pasireotide and Pasireotide LAR
Pasireotide is a medication that has been studied in a high-
quality randomised double-blind clinical trial in patients with
CD [81], and based on Phase III trial results, it has approved
in the EU and US for the treatment of adult patients with
CD for whom surgery has failed or is not an option.
In a Phase-II proof-of-concept open-label, short-term
multicentre study, designed to assess the efficacy, safety and
pharmacokinetics of pasireotide in patients with CD, subcuta-
neous pasireotide (600 mcg twice daily) was shown to reduce
UFC levels in 76% of the patients. Moreover, after 15 days of
treatment, mean 24-h UFC was normalised in 17% of
patients [82]. These results demonstrated for the first time
that pasireotide is promising as a pituitary-targeted medical
treatment for CD. Indeed, this was reinforced during a rand-
omised, double-blind multi-centre Phase-III study that
included 162 patients with persistent or recurrent disease or
who were ineligible for surgery [81]. Patients were randomised
to receive pasireotide 600 mcg (n = 82) or 900 mcg (n = 80)
subcutaneously twice daily for 12 months. Multiple UFC
measurements were used to determine efficacy. After 3 months
of treatment, patients with mean UFC of at least two times
the upper limit of the normal range or higher than baseline
were unblinded and their dose increased by 300 mcg. The
proportion of patients at 6 months with UFC levels at or
below the ULN without a prior dose increase was
12/82 patients (15%) in the 600 lg group and 21/80 patients
(26%) in the 900 lg group. Decreases in UFC from baseline
to months 6 and 12 were statistically significant in both treat-
ment groups (p < 0.001). Overall, signs and symptoms
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improved as mean UFC decreased. Interestingly, at
12 months, tumour volume was reduced by 9% and 44%,
in the 600 and 900 mcg groups, respectively. This Phase III
study is limited by the lack of a control group and an imbal-
ance in baseline UFC levels between the two treatment
groups, which may have had an effect on outcome. The
patients had improvement in blood pressure, an average
6.7-kg decrease in weight and improvement in their physical
appearance. Pasireotide was most effective in those with
milder disease. Although efficacy is usually seen within weeks,
here normalisation of cortisol levels was achieved after months
of treatment. It is conceivable that this late effect might be due
to the reactivation of different SSTR, especially SSTR2, in
concomitance with cortisol decrease. It is noteworthy that
short-term results are not always predictive of long-term out-
comes. Several case reports also suggest that there is no loss of
efficacy after long-term therapy with pasireotide [83-85],
although more data are needed.
Although pasireotide has a generally tolerability profile simi-
lar to that of other somatostatin analogues, it is associated with a
relatively high incidence of hyperglycaemia, requiring the addi-
tion or intensification of glucose-lowering medication in a sub-
stantial proportion of patients. In the Phase III study, 73% of
patients experienced glucose metabolism changes reported as
hyperglycaemia (40%), diabetes mellitus (18%) or increased
HbA1c (11%) [81]. Two studies in healthy volunteers elucidated
the mechanism of action of hyperglycaemia associated with
pasireotide administration and identified the increase in glucose
levels as secondary to a marked inhibition of insulin and incre-
tin secretion (both glucagon-like peptide-1 [GLP-1] and gastric
inhibitory polypeptide [GIP]), with minimal inhibition of glu-
cagon secretion and no impact on insulin sensitivity. Incretin-
based anti-hyperglycaemic agents such as dipeptidyl
peptidase-4 (DPP-4) inhibitors (e.g., vildagliptin) and
GLP-1 analogues (e.g., liraglutide), followed by insulin secreta-
gogues (e.g., nateglinide), may be able to ameliorate the effects
of pasireotide on glucose homeostasis [86]. Further research into
hyperglycaemia following pasireotide treatment will help refine
the optimal strategy in CD. Other adverse effects related with
pasireotide treatment were hypocortisolism (8%) [81], pro-
longed QT interval and decreased heart rate [87].
Long-acting pasireotide formulations, with a monthly dose
frequency, have been developed to reduce the number of
injections from twice a day to once a month in order to
enhance convenience and improve its effectiveness. The use
of this formulation is currently being investigated in CD,
and enrolment is complete.
7. Potential development issues
7.1 Combination therapy
An additional potential line of development could be the
realisation of more trials exploring the effectiveness of combi-
nation therapy on CD. Combination therapy has two major
advantages. First, when approaching desperately ill patients it
may guarantee an efficient and rapid inhibition of cortisol pro-
duction. Second, by combining different mechanisms to
improve hypercortisolism, they may provide improved efficacy
with fewer side effects as lower doses of each drug may be used.
In a study of 14 patients with CD, a combination of keto-
conazole and cabergoline achieved 24-h UFC normalisation
in 79% of the patients [88]. The addition of ketoconazole to
cabergoline and vice versa was effective, with no difference
regarding which agent was initiated first [88]. This prospective
analysis divided 14 patients (f/m = 12/2; median age 52, range
33 -- 70 years) into two groups: 6 patients initially treated
with cabergoline for 4 -- 6 months (rising from 0.5 -- 1 mg/
week up to 3.0 mg/week), after which ketoconazole was added
(group A); and 8 patients first took ketoconazole alone for
4 -- 6 months (rising from 200 mg/day to 600 mg/day),
then cabergoline was added (group B). Patients were com-
pared with 14 age-matched patients in prolonged remission
after effective neurosurgery for CD. The combination therapy
led to UFC normalisation in 79% of patients with no differ-
ences between the groups; only one patient failed to respond
at all. Neither drug succeeded in controlling the disease
when taken alone. Associating cabergoline with ketoconazole
may represent an effective second-line treatment, achieving a
satisfactory reduction in UFC levels and clinical improve-
ment. Although the combined treatment lowered patients’
LNSC levels, they remained higher than normal, indicating
a persistent subclinical hypercortisolism; the implications of
this finding need to be considered.
Feelders et al. [83] conducted an 80-day study where pasir-
eotide was initially administered as monotherapy, and caber-
goline and low-dose ketoconazole were sequentially added at
4 and 8 weeks, respectively, as normalisation of urinary corti-
sol levels was achieved. This approach achieved normalisation
in 90% of patients. Pasireotide monotherapy normalised
UFC in 5 out of 17 patients (29%). Cabergoline addition
resulted in normalisation in another four patients (24%),
and all other patients, except one, experienced a mean 48%
reduction in urinary cortisol levels. The addition of ketocona-
zole resulted in normalisation of urinary cortisol in six addi-
tional patients (35%). In another study, the addition of
ketoconazole to cabergoline also increased the proportion of
patients who achieved normalisation of urinary cortisol [84].
In a small study of patients with ACTH-dependent Cushing
syndrome, which included four patients with CD with severe
hypercortisolism (24-h UFC > 832 µg/day; normal,
10 -- 65 µg/day), low or normal 24-h UFC was achieved in
all patients with triple combination therapy of ketoconazole,
metyrapone and mitotane [85]. The patients underwent pitui-
tary surgery 5 -- 22 months after initiation of combination
therapy. Three patients achieved remission postoperatively,
and one patient needed to resume medical therapy when
hypercortisolism recurred. Adverse effects were tolerable, con-
sisting mainly of gastrointestinal discomfort and a significant
rise in total cholesterol and g-glutamyltransferase levels.
D. Guelho & A. B. Grossman
12 Expert Opin. Emerging Drugs (2015) 20(3)
Ex
pe
rt 
O
pi
n.
 E
m
er
gi
ng
 D
ru
gs
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
07
/0
3/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
Although the remission rates in these small studies are very
encouraging, none of the combination therapies is currently
approved in patients with CD. There is clearly a need for fur-
ther studies examining the potential of combination therapies
in these patients.
There is also a scientific rationale for combining pituitary-
directed agents for the management of CD. Corticotroph
cells co-express both somatostatin and dopamine receptors,
which work synergistically through membrane interaction or
dimerisation [89,90]. Studies on different tumour models,
including pituitary adenomas, revealed a higher potency of
BIM-23A779, BIM-23A760 and BIM-23A781 (chimeric
molecules containing both SST and dopamine structural ele-
ments) in controlling tumour cell growth [91]. If the functional
heterodimerisation of these receptors occurs in vivo, as has
already been demonstrated in vitro, the combination of caber-
goline plus pasireotide and/or other SSTR5-targeted somato-
statin analogues and/or BIM23A760 (a chimeric dopamine-
somatostatin receptor agonist) could be an exciting concept,
increasing the medical options for these patients.
A prospective, Phase II trial assessing pasireotide, alone or
in combination with cabergoline, in patients with CD is on-
going. In this study, 128 adult patients with persistent, recur-
rent or de novo CD will be enrolled and stratified into one of
two groups: group 1 is pasireotide naive or with treatment
discontinued ‡ 4 weeks before screening because of lack of
efficacy; and, group 2 received maximum tolerated dose of
pasireotide for ‡ 8 weeks, without biochemical control.
The primary end point of the study is to evaluate the propor-
tion of patients of group 1 with mean urinary free
cortisol £ ULN at week 35 with pasireotide alone or in com-
bination with cabergoline, and the proportion of patients of
group 2 with mean urinary free cortisol £ ULN at week
17 with pasireotide in combination with cabergoline [92].
8. Conclusion
CD is a severe and complex entity which needs aggressive and
rapid curative treatment due to its long-term sequelae. Unfor-
tunately, current therapeutic options, even in the hands of the
most specialised centres, do not achieve cure in a significant
proportion of patients. Considering the effects of uncon-
trolled hypercortisolism on morbidity and mortality and the
drawbacks of RT and bilateral adrenalectomy, there is a clear
need for effective medical therapy for patients with CD with
whom surgery is unsuccessful or not feasible. Therefore, the
search for new medical effective tools remains open, and novel
options are currently being explored.
9. Expert opinion
We now have a number of different agents available for the
control of the clinical manifestations of hypercortisolism in
varying situations. When rapid control of the hypercortisolae-
mia of CD is required, metyrapone is the drug of choice as it
works within hours and is highly effective in some 75% of
patients. However, in the long-term, it causes virilisation in
women. Ketoconazole is a good second-line drug, is probably
slower in onset and slightly less effective than metyrapone, but
can also be used in combination. LCI699 is similar to metyr-
apone but more potent and longer-acting, and may in the
future be a better alternative, but more data are required.
Mifepristone is expensive and difficult to monitor, but can
be used as oral medication in patients where metyrapone or
ketoconazole are inappropriate: we do not see its extensive
use. Where a rapid response is required and the patient is in
extremis, intravenous etomidate can be life-saving.
It is difficult to prognosticate regarding future adrenostatic
or adrenolytic drugs for CD. At present, the array we have
available are moderately effective and often complementary,
and the recent licensing for metyrapone and ketoconazole in
particular is a welcome innovation for endocrinologists.
LCI699 may have certain advantages over metyrapone, and
if marketed might also provide competitive positioning with
metyrapone such that overall costs will fall. At present, it
seems unlikely that the availability of the specifically-active
enantiomer of ketoconazole will offer any major advantages,
although again such a new entry to the market may have
cost benefits for patients and clinicians. It seems improbable,
at present, that there will be any other new entrants to this
arena in the immediate future.
For drugs working directly on the pituitary, cabergoline is
occasionally effective, although escape may occur, but it is
readily available. Pasireotide can be used in patients with
mild CD, although its use is hampered by high cost and signif-
icant hyperglycaemia. We do not personally feel that this will
play a major role in the treatment of CD, not least because
of its high cost and diabetogenic potential. The real require-
ment is for an orally active drug effective in the majority of
patients with CD with no major adverse effects, and none is
currently foreseen. It is possible that combined dopamine-
somatostatin analogues will be more useful than pasireotide,
but it would seem that any somatostatin subtype 5 receptor
agonist is going to be a potent inhibitor of incretins and insu-
lin, which is a powerful disincentive to their use.
As most corticotroph tumours respond to CRH with the
release of ACTH, potent CRH-antagonists may be a
completely novel approach, and their development should
be encouraged. As an alternative approach, botulinum toxin
can be linked to a CRH ligand and therefore target cortico-
troph cells to block ACTH secretion and possibly also tumour
cell viability. Such a development would be even more
innovative, and we would be strongly supportive of pharma-
ceutical research and innovation in this area.
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